CRISPR Therapeutics (NASDAQ:CRSP) shares saw unusually-high trading volume on Friday . Approximately 2,772,366 shares traded hands during trading, an increase of 145% from the previous session’s volume of 1,132,946 shares.The stock last traded at $43.27 and had previously closed at $43.27.
CRSP has been the topic of a number of recent research reports. Cann reiterated a “hold” rating on shares of CRISPR Therapeutics in a report on Sunday, December 10th. JMP Securities initiated coverage on shares of CRISPR Therapeutics in a report on Thursday, March 8th. They set an “outperform” rating and a $69.00 price target on the stock. ValuEngine upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. SunTrust Banks reiterated a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a report on Friday, March 9th. Finally, TheStreet upgraded shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, March 16th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $63.95.
In related news, insider Tyler Dylan-Hyde sold 66,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total value of $1,849,980.00. Following the transaction, the insider now owns 25,204 shares in the company, valued at $706,468.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. 39.98% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC acquired a new position in CRISPR Therapeutics in the fourth quarter valued at $20,160,000. Franklin Resources Inc. lifted its holdings in CRISPR Therapeutics by 8.9% in the fourth quarter. Franklin Resources Inc. now owns 794,533 shares of the company’s stock valued at $18,656,000 after buying an additional 65,200 shares during the period. Global Thematic Partners LLC lifted its holdings in CRISPR Therapeutics by 11.2% in the fourth quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock valued at $14,873,000 after buying an additional 63,611 shares during the period. BlackRock Inc. lifted its holdings in CRISPR Therapeutics by 16,623.9% in the fourth quarter. BlackRock Inc. now owns 552,558 shares of the company’s stock valued at $12,974,000 after buying an additional 549,254 shares during the period. Finally, Opaleye Management Inc. acquired a new position in CRISPR Therapeutics in the fourth quarter valued at $6,597,000. Institutional investors and hedge funds own 26.61% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/crispr-therapeutics-crsp-sees-large-volume-increase.html.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.